Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker.

Waterworth DM, Li L, Scott R, Warren L, Gillson C, Aponte J, Sarov-Blat L, Sprecher D, Dupuis J, Reiner A, Psaty BM, Tracy RP, Lin H, McPherson R, Chissoe S, Wareham N, Ehm MG.

J Am Heart Assoc. 2014 Aug 27;3(4). pii: e001074. doi: 10.1161/JAHA.114.001074.

2.

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators.

Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.

PMID:
24930728
3.

Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.

Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, Brannan SP, Tarka EA, Shaddinger BC, Sarov-Blat L, Matthews P, Subramanian S, Farkouh M, Fayad ZA.

J Am Coll Cardiol. 2014 Jan 7-14;63(1):86-8. doi: 10.1016/j.jacc.2013.07.050. Epub 2013 Aug 21. No abstract available.

4.

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J.

Br J Clin Pharmacol. 2013 Jul;76(1):99-106. doi: 10.1111/bcp.12063.

5.

The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.

Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK.

Am Heart J. 2012 Nov;164(5):646-653.e3. doi: 10.1016/j.ahj.2012.07.030. Epub 2012 Oct 16.

PMID:
23137494
6.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.

JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22. doi: 10.1016/j.jcmg.2012.02.016.

7.

Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB.

Circulation. 2011 Feb 8;123(5):515-23. doi: 10.1161/CIRCULATIONAHA.110.971986. Epub 2011 Jan 24.

PMID:
21262998
8.

Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans.

Sarov-Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, Baidoo C, Willette RN, Lepore JJ, Jensen SE, Sprecher DL.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2256-63. doi: 10.1161/ATVBAHA.110.209205. Epub 2010 Aug 5.

PMID:
20689074
9.

In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats.

Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, Ohlstein EH, Willette RN.

J Pharmacol Exp Ther. 2008 May;325(2):466-74. doi: 10.1124/jpet.107.135327. Epub 2008 Feb 20.

PMID:
18287212
10.

Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature.

Mohler ER 3rd, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A, Macphee C, Llano R, Pelchovitz D, Mainigi SK, Osman H, Hallman T, Steplewski K, Gertz Z, Lu MM, Wilensky RL.

Arterioscler Thromb Vasc Biol. 2008 May;28(5):850-5. doi: 10.1161/ATVBAHA.107.154534. Epub 2008 Feb 14.

PMID:
18276914
11.

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F.

Diabetes. 2008 Feb;57(2):332-9. Epub 2007 Nov 16.

12.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN.

J Cardiovasc Pharmacol. 2007 Jul;50(1):25-34.

PMID:
17666912
13.

Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol.

Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1115-22. Epub 2007 Feb 22.

PMID:
17322100
14.

Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux.

Haidar B, Kiss RS, Sarov-Blat L, Brunet R, Harder C, McPherson R, Marcel YL.

J Biol Chem. 2006 Dec 29;281(52):39971-81. Epub 2006 Oct 10.

15.

Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.

Jaye MC, Krawiec JA, Campobasso N, Smallwood A, Qiu C, Lu Q, Kerrigan JJ, De Los Frailes Alvaro M, Laffitte B, Liu WS, Marino JP Jr, Meyer CR, Nichols JA, Parks DJ, Perez P, Sarov-Blat L, Seepersaud SD, Steplewski KM, Thompson SK, Wang P, Watson MA, Webb CL, Haigh D, Caravella JA, Macphee CH, Willson TM, Collins JL.

J Med Chem. 2005 Aug 25;48(17):5419-22.

PMID:
16107141
16.

Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model.

Douglas SA, Ao Z, Johns DG, Maniscalco K, Willette RN, Sarov-Blat L, Cogswell JP, Seepersaud S, Murdock P, Steplewski KM, Patel L.

Methods Mol Biol. 2005;306:27-49. No abstract available.

PMID:
15867463
17.

Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.

Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Oct;370(4):238-50. Epub 2004 Sep 30.

PMID:
15549273
18.

Human epicardial adipose tissue is a source of inflammatory mediators.

Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y.

Circulation. 2003 Nov 18;108(20):2460-6. Epub 2003 Oct 27.

PMID:
14581396
19.
20.

takeout, a novel Drosophila gene under circadian clock transcriptional regulation.

So WV, Sarov-Blat L, Kotarski CK, McDonald MJ, Allada R, Rosbash M.

Mol Cell Biol. 2000 Sep;20(18):6935-44.

21.

Supplemental Content

Loading ...
Support Center